NewAmsterdam Pharma Company N.V.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Quarterly earnings show how the company is performing financially and help investors track progress over time.
The full quarterly report contains balance sheet and cash details that show company health beyond just earnings.
Positive approval recommendation for two medicines could lead to sales and proves the company's drugs work.
Leadership changes can affect company strategy and operations, so investors need to know who runs the business.
Employee stock plans can dilute existing shareholders but help attract and keep talented workers.
Quarterly earnings show how the company is performing financially and help investors track progress over time.
The full quarterly report contains balance sheet and cash details that show company health beyond just earnings.
Stocky reads NewAmsterdam Pharma Company N.V.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
NewAmsterdam Pharma Company N.V.'s most recent tracked filing was a 8-K on 5 Aug 2026: NewAmsterdam reports Q2 2026 financial results and updates.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.